KR20130102307A - Composition for improving heart and liver function and functional food comprising thererof - Google Patents
Composition for improving heart and liver function and functional food comprising thererof Download PDFInfo
- Publication number
- KR20130102307A KR20130102307A KR1020120023452A KR20120023452A KR20130102307A KR 20130102307 A KR20130102307 A KR 20130102307A KR 1020120023452 A KR1020120023452 A KR 1020120023452A KR 20120023452 A KR20120023452 A KR 20120023452A KR 20130102307 A KR20130102307 A KR 20130102307A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- heart
- liver
- liver function
- improving
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 79
- 210000002216 heart Anatomy 0.000 title claims abstract description 57
- 230000003908 liver function Effects 0.000 title claims abstract description 45
- 230000004217 heart function Effects 0.000 title claims abstract description 41
- 235000013376 functional food Nutrition 0.000 title claims abstract description 15
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 36
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 27
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 26
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 22
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 22
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 20
- 229940110767 coenzyme Q10 Drugs 0.000 claims abstract description 20
- 229960003080 taurine Drugs 0.000 claims abstract description 18
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 13
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 13
- 229940046009 vitamin E Drugs 0.000 claims abstract description 13
- 239000011709 vitamin E Substances 0.000 claims abstract description 13
- 229940088594 vitamin Drugs 0.000 claims abstract description 10
- 229930003231 vitamin Natural products 0.000 claims abstract description 10
- 235000013343 vitamin Nutrition 0.000 claims abstract description 10
- 239000011782 vitamin Substances 0.000 claims abstract description 10
- 241001465754 Metazoa Species 0.000 claims abstract description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 8
- 239000011701 zinc Substances 0.000 claims description 8
- 229910052725 zinc Inorganic materials 0.000 claims description 8
- 210000004185 liver Anatomy 0.000 abstract description 19
- 230000006378 damage Effects 0.000 abstract description 10
- 230000006870 function Effects 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 25
- 230000000694 effects Effects 0.000 description 21
- 206010067125 Liver injury Diseases 0.000 description 12
- 231100000234 hepatic damage Toxicity 0.000 description 12
- 230000008818 liver damage Effects 0.000 description 12
- 210000002064 heart cell Anatomy 0.000 description 11
- 210000005229 liver cell Anatomy 0.000 description 10
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 8
- 208000019425 cirrhosis of liver Diseases 0.000 description 7
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- -1 lyophilizers Substances 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- 208000006029 Cardiomegaly Diseases 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010002906 aortic stenosis Diseases 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000003683 cardiac damage Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 102100030497 Cytochrome c Human genes 0.000 description 2
- 108010075031 Cytochromes c Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940107218 chromium Drugs 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229940014144 folate Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229960003284 iron Drugs 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940091250 magnesium supplement Drugs 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- BQMPVGMHZKZPBH-BYZBDTJCSA-N (3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O.C[N+](C)(C)C[C@H](O)CC([O-])=O BQMPVGMHZKZPBH-BYZBDTJCSA-N 0.000 description 1
- 229940005561 1,4-benzoquinone Drugs 0.000 description 1
- 150000005208 1,4-dihydroxybenzenes Chemical class 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000015782 Electron Transport Complex III Human genes 0.000 description 1
- 108010024882 Electron Transport Complex III Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 239000000524 Thiobarbituric Acid Reactive Substance Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 150000004054 benzoquinones Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008359 glycogelatin Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000001451 organic peroxides Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 125000004151 quinonyl group Chemical group 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0612—Carnitine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0644—Taurine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1642—Zinc
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/30—Other Organic compounds
- A23V2250/314—Ubiquinone, coenzyme Qn
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/712—Vitamin E
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
본 발명은 심장 및 간 기능 개선용 조성물 및 이를 포함하는 기능성 식품에 대한 것으로, 구체적으로 심장 및 간 손상을 예방하고 심장 및 간 기능을 개선하는 심장 및 간 기능 개선용 조성물 및 이를 포함하는 기능성 식품에 대한 것이다.The present invention relates to a composition for improving heart and liver function and a functional food comprising the same, and specifically to a composition for improving heart and liver function and a functional food comprising the same, which prevents heart and liver damage and improves heart and liver function. It is about.
간은 우리 몸에서 가장 큰 장기로서 각종 대사작용, 해독, 분해, 합성 및 분비를 담당하는 매우 중요한 장기이다. 간은 전신을 방어하는 기능을 수행하고 있고 영양소 이외에도 많은 독성물질에 노출될 위험이 다른 장기보다 많아 그만큼 손상될 확률도 매우 높다. 간은 재생능력이 우수한 장기로 약간의 손상이 있을 경우에는 충분히 정상으로 회복된다. 그러나, 손상이 지속될 경우에는 간 조직의 일부가 완전히 파괴되고 간 기능도 저하되는 등 회복이 어려운 상태가 된다. 이러한 간 손상이 만성화되면 그 원인에 상관없이 간 섬유화 또는 간경화, 간암으로 진행된다. 간 섬유화, 간경화, 간암 등은 현재 뚜렷한 치료제 및 치료법이 없는 질환으로 그 사망률 또한 높은 질환이다. 그러므로 간 손상이 만성화되기 전에 이러한 간 손상을 예방 및 치료하는 것이 간 섬유화, 간경화 또는 간암으로의 진행을 억제하는데 매우 중요하다. The liver is the largest organ in our body and is a very important organ responsible for various metabolism, detoxification, decomposition, synthesis and secretion. The liver functions to defend the body and is more likely to be damaged than other organs because of the risk of exposure to many toxic substances in addition to nutrients. The liver is a good organ with good regenerative capacity and can recover normally if there is some damage. However, if the damage persists, a part of the liver tissue is completely destroyed and liver function is also degraded. If such liver damage is chronicized, liver fibrosis, cirrhosis, and liver cancer occur regardless of the cause. Liver fibrosis, liver cirrhosis, and liver cancer are diseases that do not have clear treatments and treatments at present and their mortality rates are also high. Therefore, prevention and treatment of liver damage before liver damage is chronic is crucial to inhibiting progression to liver fibrosis, cirrhosis, or liver cancer.
한편, 심장은 정맥으로부터 혈액을 받아들여 동맥을 통해 끊임없이 혈액을 전신에 순환시키는 역할을 한다. 심장이 혈액을 송출하기 위해서는 수축하게 되는데 이러한 수축 작용을 일으키는 것은 근육으로 구성되어 있는 심근이다. 이와 관련하여 고혈압증이나 심장 판막증에 의한 심실 부하의 증대, 심근 경색, 심근염 또는 심근증 등에 의한 심근 세포 자체 장애 발생시 혈액량을 전신의 장기에 충분히 송출하지 못하여 심박출량이 감소하고 심장비대 현상을 유발하게 된다. 심장은 발생학적으로 분화가 완전히 종결된 기관으로 더 이상의 세포증식이 불가능하다. 따라서, 심장의 기능 (cardiac output)을 증가시켜야 할 필요가 생기면, 기존의 심장근 세포의 크기를 증가시켜 심근의 수축능력 (contractility)를 올리는 것이 유일한 대책인데 이런 생리현상을 심근비대 (hypertrophy)라고 한다. 이러한 심근비대가 일정 기간 지속되면 심부전으로 악화될 수 있는 가능성이 매우 높다.The heart, on the other hand, takes blood from the veins and circulates blood throughout the arteries throughout the body. The heart contracts to deliver blood, which causes the myocardium, which is composed of muscles. In this regard, when cardiac myocardial cell disorders occur due to an increase in ventricular load due to hypertension or heart valve syndrome, myocardial infarction, myocarditis, or cardiomyopathy, blood volume may not be sufficiently transmitted to organs of the whole body, resulting in decreased cardiac output and cardiac hypertrophy. The heart is an organ that has been completely differentiated and cannot further cell proliferation. Therefore, if there is a need to increase the cardiac output, the only solution is to increase the size of the existing cardiomyocytes and increase the contractility of the myocardium. This physiological phenomenon is called hypertrophy. . If this myocardial hypertrophy lasts for a certain period of time, it is very likely that it can worsen with heart failure.
본 발명이 해결하고자 하는 과제는 심장 및 간 손상을 예방하고 심장 및 간 기능을 개선하는 심장 및 간 기능 개선용 조성물을 제공하는 것이다.The problem to be solved by the present invention is to provide a composition for improving heart and liver function to prevent heart and liver damage and improve heart and liver function.
본 발명이 해결하려는 다른 과제는 심장 및 간 손상을 예방하고 심장 및 간 기능을 개선하는 심장 및 간 기능 개선용 기능성 식품을 제공하는 것이다. Another problem to be solved by the present invention is to provide a functional food for improving heart and liver function to prevent heart and liver damage and improve heart and liver function.
본 발명의 기술적 과제들은 이상에서 언급한 기술적 과제로 제한되지 않으며, 언급되지 않은 또 다른 기술적 과제들은 아래의 기재로부터 당업자에게 명확하게 이해될 수 있을 것이다.The technical objects of the present invention are not limited to the technical matters mentioned above, and other technical subjects not mentioned can be clearly understood by those skilled in the art from the following description.
상기 과제를 해결하기 위해, 본 발명의 일 실시예에 따른 심장 및 간 기능 개선용 조성물은 L-카르니틴, 타우린, 및 비타민 E, 코엔자임 Q10 또는 이들의 혼합물에서 선택된 비타민류를 포함한다. In order to solve the above problems, the composition for improving heart and liver function according to an embodiment of the present invention includes L-carnitine, taurine, and vitamins selected from vitamin E, coenzyme Q10 or a mixture thereof.
상기 과제를 해결하기 위해, 본 발명의 일 실시예에 따른 심장 및 간 기능 개선용 기능성 식품은 L-카르니틴, 타우린, 및 비타민 E, 코엔자임 Q10 또는 이들의 혼합물에서 선택된 비타민류를 포함한다.In order to solve the above problems, the functional food for improving heart and liver function according to an embodiment of the present invention includes vitamins selected from L-carnitine, taurine, and vitamin E, coenzyme Q10 or mixtures thereof.
기타 실시예들의 구체적인 사항들은 상세한 설명에 포함되어 있다.The details of other embodiments are included in the detailed description.
본 발명의 실시예 들에 따른 조성물은 유해 물질의 세포내 침투 및 간 세포내 물질의 유출을 방지하여 간세포를 보호한다.The composition according to the embodiments of the present invention protects the hepatocytes by preventing intracellular penetration of harmful substances and outflow of hepatic intracellular substances.
본 발명의 실시예 들에 따른 조성물은 손상된 심장 및 간 세포의 재생을 촉진함으로서 간 기능 개선에 효과적이다. Compositions according to embodiments of the present invention are effective in improving liver function by promoting regeneration of damaged heart and liver cells.
본 발명의 실시예 들에 따른 조성물은 항산화 작용을 하여 심장 및 간세포의 손상을 막아 심장 및 간을 보호한다. Compositions according to embodiments of the present invention to prevent heart and liver cells damage by the antioxidant action to protect the heart and liver.
본 발명의 실시예 들에 따른 조성물은 콜라겐 합성을 저해하여 간 섬유화를 예방함으로써 간 손상을 예방한다. 본 발명의 조성물은 제형화에 구애받지 않고 다양한 제형의 식품 등으로 제조될 수 있으며, 다양한 식품에 첨가물처럼 활용하는 것도 가능하다. 본 발명의 실시예 들에 따른 조성물은 인간 뿐 아니라, 개, 고양이 등의 애완 동물에게도 효과가 있어 애완동물용 간식 및 식품으로 제조 가능하다. The composition according to the embodiments of the present invention prevents liver damage by inhibiting collagen synthesis and preventing liver fibrosis. The composition of the present invention can be prepared as a variety of foods and the like, regardless of the formulation, it is also possible to use as an additive to a variety of food. Compositions according to the embodiments of the present invention is effective not only for humans, but also for pets such as dogs and cats, and can be prepared as a snack and food for pets.
본 발명에 따른 효과는 이상에서 예시된 내용으로 제한되지 않으며, 더욱 다양한 효과들이 본 명세서 내에 포함되어 있다.The effects according to the present invention are not limited to the contents exemplified above, and more various effects are included in the specification.
본 발명의 이점 및 특징, 그리고 그것들을 달성하는 방법은 상세하게 후술되어 있는 실시예들을 참조하면 명확해질 것이다. 그러나 본 발명은 이하에서 개시되는 실시예들에 한정되는 것이 아니라 서로 다른 다양한 형태로 구현될 수 있으며, 단지 본 실시예들은 본 발명의 개시가 완전하도록 하고, 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 발명의 범주를 완전하게 알려주기 위해 제공되는 것이며, 본 발명은 청구항의 범주에 의해 정의될 뿐이다.Advantages and features of the present invention and methods of achieving them will become apparent with reference to the embodiments described in detail below. The present invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. To fully disclose the scope of the invention to those skilled in the art, and the invention is only defined by the scope of the claims.
본 명세서에서, 단수형은 문구에서 특별히 언급하지 않는 한 복수형도 포함하며, "포함한다(comprises)" 및/또는 "포함하는(comprising)" 은 하나 이상의 다른 구성요소의 존재 또는 추가를 배제하지 않는다. In the present specification, the singular forms include plural forms unless the context clearly dictates otherwise, and "comprises" and / or "comprising" do not exclude the presence or addition of one or more other constituents.
이하, 당업자가 명확하게 이해할 수 있도록 본 발명을 상세하게 설명한다.Hereinafter, the present invention will be described in detail so that those skilled in the art can clearly understand.
본 발명의 일 실시예에 따른 심장 및 간 기능 개선용 조성물은 L-카르니틴(L-carnitine)(A), 타우린(taurine)(B), 비타민류(C) 등을 더 포함한다. 본 발명의 일 실시예에 따른 심장 및 간 기능 개선용 조성물은 손상된 심장 및 간 세포의 재생을 촉진하고, 항산화 작용을 하여 활성 산소로 인한 간 및 심장의 손상을 예방할 뿐만 아니라 심장 및 간 기능을 향상시키는 역할을 한다. The composition for improving heart and liver function according to an embodiment of the present invention further includes L-carnitine (L-carnitine) (A), taurine (B), vitamins (C), and the like. The composition for improving heart and liver function according to an embodiment of the present invention promotes the regeneration of damaged heart and liver cells, and acts as an antioxidant to prevent damage to the liver and heart due to free radicals as well as to improve heart and liver function. It plays a role.
L-카르니틴(A)은 심장 및 간 세포의 재생을 촉진하고 심장 및 간 기능을 개선하는 역할을 한다. L-카르니틴(A)은 심근, 간 등에 필요한 영양성분으로 심장 및 간 세포의 건강을 유지시키고 손상된 심장 및 간 세포의 재생을 촉진하여 심장 및 간의 기능 개선에 기여한다. 또한, 생체내에서 산화에 의해 유리 라디칼의 증가되고 미토콘드리아 활성을 감소시키게 되는데 L-카르니틴은 미토콘드리아를 재활성시켜 유리 라디칼을 감소시킬 수 있으며, 이는 활성 산소에 의한 심장 및 간 세포의 손상을 억제하는 역할을 할 수 있다. 이외에 L-카르니틴은(A)은 심장의 대사에도 영향을 미쳐 심장 기능을 개선시킬 수 있다.L-carnitine (A) serves to promote the regeneration of heart and liver cells and to improve heart and liver function. L-carnitine (A) is a nutrient required for myocardium, liver and the like, and maintains the health of heart and liver cells and promotes the regeneration of damaged heart and liver cells, thereby contributing to the improvement of heart and liver function. In addition, oxidation in vivo increases free radicals and decreases mitochondrial activity. L-carnitine can reactivate mitochondria to reduce free radicals, which inhibits damage to heart and liver cells by free radicals. Can play a role. In addition, L-carnitine (A) can also affect the metabolism of the heart, thereby improving heart function.
L-카르니틴(A)은 조성물에 대해 10 내지 35 중량부로 포함될 수 있다. L-카르니틴(A)이 상기 범위로 포함되는 경우 심장 및 간 기능 개선 효과가 우수하다.L-carnitine (A) may be included in an amount of 10 to 35 parts by weight based on the composition. When L-carnitine (A) is included in the above range, the effect of improving heart and liver function is excellent.
타우린(B)은 심장 근육의 수축력을 강화시켜 심근 비대를 예방하는 효과가 있으며, 항산화 작용을 하여 체내 각종 자유 라디칼(free radicals)을 중화하는 역할을 하므로 간의 해독작용을 도울 수 있다. 또한, 세포 내 삼투압을 변화시켜 심장을 보호하고 심근 세포내 활성과 기능에 영향을 미치는 칼슘 이온에도 영향을 미쳐 심장 및 간 기능을 향상시키는 역할을 한다. 또한, 타우린(B)이 L-카르니틴(A)과 함께 사용되는 경우 심장 및 간 기능 개선 효과가 더욱 향상된다. Taurine (B) has the effect of preventing the myocardial hypertrophy by strengthening the contractile force of the heart muscle, and acts as an antioxidant to neutralize various free radicals in the body can help the liver detoxification. In addition, it protects the heart by changing the intracellular osmotic pressure, and also affects calcium ions that affect the activity and function of myocardial cells, thereby improving heart and liver function. In addition, when taurine (B) is used together with L-carnitine (A), the effect of improving heart and liver function is further improved.
타우린(B)은 조성물에 대해 1 내지 30 중량부로 포함될 수 있으며, 구체적으로 10 내지 20 중량부로 포함될 수 있다. 타우린(B)이 상기 범위로 포함되는 경우 L-카르니틴(A)과 함께 심장 및 간 기능 개선에 우수한 효과를 나타낼 수 있다. Taurine (B) may be included in an amount of 1 to 30 parts by weight, and specifically 10 to 20 parts by weight, based on the composition. When taurine (B) is included in the above range, L-carnitine (A) may exhibit an excellent effect on improving heart and liver function.
비타민류(C)는 코엔자임 Q10(coenzyme Q10)(C-1), 비타민 E(C-2), 또는 이들의 혼합물에서 선택된 단독 또는 이들의 혼합물을 사용할 수 있다. Vitamins (C) may be used alone or a mixture thereof selected from coenzyme Q10 (C-1), vitamin E (C-2), or a mixture thereof.
코엔자임 Q10(C-1)은 코엔자임 Q10 은 유비퀴논(ubiquinone) 10, 유비데카레논 또는 조효소 UQ10 이라고도 불리며, 2,3-디메톡시-5-메틸-6-데카프레닐-1,4 벤조퀴논의 화학식을 갖는 벤조퀴논류의 비타민 유사물질이다. 코엔자임 Q10은 동·식물의 조직, 구체적으로, 세포 내의 소포체(endoplasmic reticulum), 퍼옥시좀 (peroxisomes), 리소좀(lysosomes), 미토콘드리아 내막에서 발견된다. 미토콘드리아막의 전자전달계는 복합체 I(complex I), 복합체 II(complex II), 복합체 III(complex III), 복합체 IV(complex IV) 및 두 종의 분자 즉 코엔자임 Q10 및 시토크롬 c를 포함한다. 코엔자임 Q10은 미토콘드리아와 박테리아의 호흡에 있어서 coenzyme Q: cytochrome c oxidoreductase와 같은 수용체에 환원 당량(reducing equivalent)을 전달함으로써 전자의 운반과 양자의 이동에 기여를 하여, ATP 형태의 체내 에너지 생산에 중요한 역할을 담당한다. 코엔자임 Q10의 구조는 퀴논 머리 그룹(quinonehead group)과 소수성 이소프레노이드 꼬리부(isoprenoid tail)로 이루어져 있으며, 퀴논 그룹이 퀴논, 세미퀴논(semiquinone), 하이드로퀴논(hydroquinone) 사이를 오가며 가역적 전자 전달 과정을 수행한다. Coenzyme Q10 (C-1) is also called coenzyme Q10, ubiquinone 10, ubidecarenone or coenzyme UQ10, and is known as 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4 benzoquinone. It is a vitamin-like substance of benzoquinones having the chemical formula. Coenzyme Q10 is found in tissues of animals and plants, specifically endoplasmic reticulum, peroxisomes, lysosomes, and mitochondrial linings. Electron transport systems of mitochondrial membranes include complex I, complex II, complex III, complex IV and two molecules, coenzyme Q10 and cytochrome c. Coenzyme Q10 plays an important role in the production of ATP-type energy in the body by contributing to the transport of electrons and proton transport by delivering reducing equivalents to receptors such as coenzyme Q: cytochrome c oxidoreductase in mitochondrial and bacterial respiration. In charge of. The structure of coenzyme Q10 consists of a quinonehead group and a hydrophobic isoprenoid tail, and a quinone group moves between quinones, semiquinones and hydroquinones and is reversible electron transfer process. Do this.
본 발명에 따른 코엔자임 Q10(C-1)은 소 등의 동물의 심장으로부터 추출된 것이어도 되고, 합성법, 발효법으로 얻은 것이어도 무방하며, 특별히 제한되지 않는다. 본 발명에 따른 코엔자임 Q10(C-1)은 인체 세포와 조직의 항산화 작용을 강화시켜 심혈관계 질환을 상승시키는 역할을 하며, 특히 상술한 L-카르니틴(A) 및 타우린(B)과 조합하여 사용하는 경우 심장 기능의 개선 효과를 더욱 상승시킨다. 또한, 항산화 작용에 의해 자유 라디칼에 의한 간 세포 및 심장 세포의 손상을 막는 역할을 함으로써 심장 및 간을 보호한다.Coenzyme Q10 (C-1) according to the present invention may be extracted from the heart of an animal such as cow, or may be obtained by a synthesis method or a fermentation method, and is not particularly limited. Coenzyme Q10 (C-1) according to the present invention serves to enhance the cardiovascular disease by enhancing the antioxidant activity of human cells and tissues, in particular used in combination with L-carnitine (A) and taurine (B) If you increase the effect of improving heart function. In addition, it protects the heart and liver by acting to prevent damage of liver cells and heart cells by free radicals by the antioxidant action.
코엔자임 Q10(C-1)은 조성물에 대해 0.1 내지 5 중량부, 보다 구체적으로 1 내지 5 중량부로 포함될 수 있다. 0.1 내지 5 중량부로 포함되는 경우 심장 및 간 세포의 손상을 방지하고 기능 개선을 향상시키는 역할을 하나 0.1 중량부 미만으로 포함되는 경우 그 효과가 미미하고, 5 중량부를 초과하는 경우 수용액 뿐만 아니라 지질 용액에도 용해도가 낮아 제형화에 어려움이 있으며, 체내 흡수도가 떨어질 수 있다. Coenzyme Q10 (C-1) may be included in an amount of 0.1 to 5 parts by weight, more specifically 1 to 5 parts by weight, based on the composition. When contained in an amount of 0.1 to 5 parts by weight to prevent damage to the heart and liver cells and to improve the function, but when contained in less than 0.1 part by weight of the effect is insignificant, when it exceeds 5 parts by weight of lipid solution as well as aqueous solution The low solubility is difficult to formulate, and the absorption in the body may be reduced.
비타민 E(C-2)는 손상된 심장 및 간 세포의 재생을 촉진하고, 심장 근육을 강화시켜 협심증 예방 및 심장 기능 개선에 향상된 효과를 나타낸다. 또한, 활성산소로부터 간세포 및 심장 세포의 손상을 억제하는 역할을 하며, 상술한 L-카르니틴(A) 및 타우린(B)의 효과가 더욱 상승될 수 있도록 하는 역할을 한다. Vitamin E (C-2) promotes the regeneration of damaged heart and liver cells, strengthens the heart muscle, and has an improved effect on preventing angina and improving heart function. In addition, it serves to inhibit the damage of hepatocytes and heart cells from free radicals, and serves to increase the effects of the above-mentioned L-carnitine (A) and taurine (B).
본 발명에 따른 비타민 E(C-2)는 비타민 E(D)는 조성물에 대하여 0.1 내지 5 중량부로 포함될 수 있다. 상기 범위로 포함되는 경우 심장 및 간 기능 개선 효과를 상승시킬 수 있다.Vitamin E (C-2) according to the present invention vitamin E (D) may be included in 0.1 to 5 parts by weight based on the composition. If included in the above range can increase the effect of improving heart and liver function.
또한, 본 발명의 실시예 들에 따른 조성물은 비타민 B1, B2, B6, C, 니아신, 베타인, 엽산 판토텐산, 비오틴, 철, 칼슘, 크롬, 아연 및 마그네슘으로 이루어진 군으로부터 선택된 단독 또는 이들의 혼합물을 더 포함할 수 있으며, 바람직하게는 아연을 더 포함할 수 있다. 상기 물질 들은 상기 활성 성분들과 조합하는 경우 활성 성분이 그 효과를 잘 발휘할 수 있도록 조력하는 한편, 신체의 활성을 증진하는데 도움을 준다. In addition, the composition according to the embodiments of the present invention is vitamin B1, B2, B6, C, niacin, betaine, folate pantothenic acid, biotin, iron, calcium, chromium, zinc and magnesium alone or mixtures thereof It may further include, preferably may further comprise zinc. The substances help to enhance the activity of the body, while helping the active ingredient to exert its effect when combined with the active ingredients.
상기 비타민 B1, B2, B6, C, 니아신, 베타인, 엽산 판토텐산, 비오틴, 철, 칼슘, 크롬, 아연 및 마그네슘으로 이루어진 군으로부터 선택된 단독 또는 이들의 혼합물은 조성물에 대하여 0.5 내지 1.0 중량부로 포함될 수 있다. 상기 범위로 포함되는 경우 활성 성분 들의 효과를 상승시키는 한편, 신체 활성을 효과적으로 증진시킬 수 있다. The vitamin B1, B2, B6, C, niacin, betaine, folate pantothenic acid, biotin, iron, calcium, chromium, zinc and magnesium alone or a mixture thereof may be included in an amount of 0.5 to 1.0 parts by weight based on the composition. have. When included in the above range can increase the effectiveness of the active ingredients, while effectively promoting physical activity.
본 발명의 실시예들에 따른 심장 및 간 기능 개선용 조성물은 경구 또는 비경구의 여러가지 제형으로 제조할 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합체, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구 투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제에는 하나 이상의 화합물에 적어도 하나 이상의 부형제 예를 들면, 전분, 탄산칼슘, 수크로스 또는 락토오스, 젤라틴 등을 섞어 조제한다. 또한, 단순한 부형제 외에 스테아린산 마그네슘, 탈크 등과 같은 윤활제등도 사용된다. 경구 투여를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순한 희석제인 무르 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면, 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균 수용액, 비수성용제, 현탁제, 유제, 동결건조제, 좌제가 포함된다. 비수성용제 및 현탁용제로는 프로필렌글리콜, 폴리에틸렌글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈 61, 카카오지, 라우틴지, 글리소로젤라틴 등이 사용될 수 있다. Compositions for improving heart and liver function according to embodiments of the present invention can be prepared in various formulations, oral or parenteral. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants are usually used. Solid form preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which include at least one excipient in one or more compounds, such as starch, calcium carbonate, sucrose or lactose, gelatin, and the like. Mix to prepare. In addition to the simple excipients, lubricants such as magnesium stearate, talc and the like are also used. Liquid preparations for oral administration include suspensions, solutions, emulsions, and syrups, and various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to mur liquid paraffin, a simple diluent commonly used. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilizers, suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, lautin paper, glycogelatin and the like can be used.
본 발명의 실시예 들에 따른 심장 및 간 기능 개선용 조성물은 다양한 기능성 식품으로 제조될 수 있다. 예를 들어, 츄잉껌, 캐러멜 제품, 캔디류, 빙과류, 과자류 등의 각종 식품류, 청량음료, 미네랄워터, 알코올 음료 등의 음료류, 비타민이나 미네랄 등 건강기능성 식품류일 수 있다. 또한, 애완 동물용 경구용 제제, 구체적으로 애완 동물용 정제, 캡슐, 액체, 겔, 페이스트, 경구용 스프레이, 구강정, 산제 및 씹어먹는 트리트(chewable treat) 또는 동물 사료 등으로 제형화될 수 있으나 이에 한정되는 것은 아니다. Compositions for improving heart and liver function according to embodiments of the present invention may be prepared in a variety of functional foods. For example, it may be chewing gum, caramel products, candy, ice cream, confectionary, various foods, soft drinks, mineral water, alcoholic beverages, and other functional foods such as vitamins and minerals. It may also be formulated as an oral preparation for pets, specifically pet tablets, capsules, liquids, gels, pastes, oral sprays, oral tablets, powders and chewable treats or animal feeds. It is not limited to this.
본 발명의 실시예 들에 따른 심장 및 간 기능 개선용 조성물은 그대로 식품으로 제조되거나 또는 다른 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효 성분의 혼합량은 사용목적에 따라 적합하게 결정될 수 있다. Compositions for improving heart and liver function according to embodiments of the present invention may be prepared as food or used with other food ingredients, and may be appropriately used according to conventional methods. The amount of the active ingredient to be mixed may be appropriately determined depending on the intended use.
본 발명의 기능성 식품은 여러가지 향미제 또는 천연 탄수화물 등을 추가성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 소르비톨, 에리스리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 건강기능식품 100중량부당 0.01~0.04 중량부, 바람직하게는 약 0.02~0.03 중량부 범위에서 선택하는 것이 바람직하다. The functional food of the present invention may contain various flavors or natural carbohydrates as additional ingredients. The above-mentioned natural carbohydrates are sugar alcohols such as monosaccharides such as glucose and fructose, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau Martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The ratio of the natural carbohydrate is preferably selected in the range of 0.01 to 0.04 parts by weight, preferably about 0.02 to 0.03 parts by weight, per 100 parts by weight of the health functional food of the present invention.
상기 외에 본 발명의 기능성 식품은 여러가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 기능성 식품은 천연 과일주스, 과일주스음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 중요하진 않지만 본 발명의 기능성 식품 100 중량부당 0.01 내지 0.1 중량부의 범위에서 선택되는 것이 일반적이다. In addition to the above, the functional food of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, And carbonating agents used in carbonated drinks. In addition, the functional food of the present invention may contain fruit flesh for the production of natural fruit juice, fruit juice drink and vegetable drink. These components can be used independently or in combination. The proportion of such additives is not critical but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the functional food of the present invention.
본 발명의 실시예 들에 따른 심장 및 간 기능 개선용 조성물 및 이를 포함하는 기능성 식품은 인간뿐 아니라 소, 말, 양, 돼지, 염소, 낙타, 영양, 등의 가축 또는 개, 고양이 등의 애완동물에게 사용될 수 있다. 특히, 고양이의 경우 타우린을 체내에서 합성하는 함량이 개에 비해 매우 적으므로 본 발명의 실시예에 따른 조성물 및 식품을 섭취하였을 때 우수한 효과를 나타낼 수 있다. Compositions for improving heart and liver function and functional foods comprising the same according to embodiments of the present invention are not only humans, but also animals such as cattle, horses, sheep, pigs, goats, camels, antelopes, or pets such as dogs and cats. Can be used. In particular, in the case of cats, since the content of synthesizing taurine in the body is very small compared to dogs, it may exhibit an excellent effect when ingesting the composition and food according to the embodiment of the present invention.
이하, 실시예를 통해 본 발명을 보다 구체적으로 설명한다. 이는 본 발명의 설명을 위한 것일 뿐, 이로 인해 본 발명의 범위가 제한되지 않는다.Hereinafter, the present invention will be described more specifically by way of examples. This is for the purpose of illustrating the present invention, and thus the scope of the present invention is not limited thereto.
<< 실시예Example 1 내지 13> 심장 및 간 기능 개선용 조성물의 제조 1 to 13> Preparation of a composition for improving heart and liver function
하기 표 1의 조성으로 혼합하여 간 보호 및 간 기능 개선용 조성물을 제조하였다. 하기 표 1의 단위는 g이다. To prepare a composition for improving liver protection and liver function by mixing to the composition of Table 1 below. The units in Table 1 are g.
<< 비교예Comparative example 1 내지 4> 간 보호 및 간 기능 개선용 조성물의 제조 1 to 4> Preparation of a composition for protecting liver and improving liver function
하기 표 2의 조성으로 혼합하여 간 보호 및 간 기능 개선용 조성물을 제조하였다. 하기 표 2의 단위는 g이다. By mixing to the composition of Table 2 to prepare a composition for liver protection and liver function improvement. The unit of Table 2 below is g.
<< 제형예Formulation Example 1> 1> 드링크의Drink 제조 Produce
하기 표 3의 조성을 혼합하고 병에 충진하여 드링크제를 제조하였다. 하기 표 3의 단위는 mg이다. The composition of Table 3 was mixed and filled into bottles to prepare a drink. The unit of Table 3 below is mg.
<< 제형예Formulation Example 2> 정제의 제조 2> Preparation of tablets
하기 표 4의 조성을 혼합하여 30% 에탄올 40 mg을 첨가하여 과립을 형성한 후, 60 ℃에서 건조하고 타정기를 이용하여 정제하여 타정하였다. 하기 표 4의 단위는 mg이다. The composition of Table 4 was mixed to form granules by adding 40 mg of 30% ethanol, dried at 60 ° C., and purified by tableting. The unit of Table 4 below is mg.
<< 실험예Experimental Example 1> 간 보호 및 간 기능 개선 효과 확인 1> Liver protection and liver function improvement
실시예 및 비교예 조성물의 간 기능 개선 효과를 확인하기 위해 5주령된 건강한 쥐를 각 조성물당 3마리씩 선별하여 간 기능 개선 효과를 확인하였다. 사염화탄소(CCl4)는 간에 독성을 주는 표본 물질로서, 간에서 복합적인 기능을 하는 시토크롬(cytochrome) P450 과 같은 대사효소에 의해 대사되어 매우 반응성이 강한 자유 라디칼인 CCl3 와 Cl을 형성하고, 자유 라디칼인 CCl3 은 축적된 간 중성지방이나 막 인지질에 있는 지방산의 산화를 유발시키고 지질 과산화 작용을 통하여 유기 과산화물을 형성한다. 지질 과산화작용을 통하여 간장에 지방이 축적되고, 단백질 합성능력은 감소하게 되어 글리코겐이 분해되고 혈관내의 세포질 효소들이 파괴되어 간조직의 괴사가 일어나게 된다. 쥐에 간손상을 주기 위해 사염화탄소를 생체 중량대비 1.2 ml/kg 경구투여한 후, 상기 실시예 및 비교예의 조성물을 약 500mg씩 20일 동안 1일 1회 경구투여하였다. 15일 후에 AST 와 ALT를 측정한 결과는 하기 표 5와 같다. 하기 초기는 간 손상을 유발한 후 실시예 및 비교예의 조성물을 투여하기 전의 결과를 나타낸다. Example and Comparative Example In order to confirm the effect of improving the liver function of the composition, 5 weeks old healthy rats were selected for each of three compositions to confirm the effect of improving liver function. Carbon tetrachloride (CCl 4 ) is a hepatotoxic sample that is metabolized by metabolic enzymes such as cytochrome P450, a complex compound in the liver, to form highly reactive free radicals CCl 3 and Cl, which are free The radical CCl 3 causes the oxidation of fatty acids in accumulated liver triglycerides or membrane phospholipids and forms organic peroxides through lipid peroxidation. Lipid peroxidation causes fat to accumulate in the liver, and protein synthesis is reduced, resulting in the breakdown of glycogen and destruction of cytoplasmic enzymes in blood vessels, resulting in necrosis of liver tissue. Carbon tetrachloride was orally administered 1.2 ml / kg of body weight to give liver damage to rats, and the compositions of Examples and Comparative Examples were orally administered once daily for 20 days. After 15 days, the results of measuring AST and ALT are shown in Table 5 below. The following initial shows the results after administration of the composition of Examples and Comparative Examples after causing liver damage.
상기 표 5에 나타난 바와 같이, 실시예 2, 3 및 6의 조성물을 경구투여한 경우 ALT 및 AST 활성이 가장 크게 감소하였으며, 실시예의 조성물을 투여한 경우 비교예의 조성물을 투여한 경우보다 더 많이 감소하였다. 따라서, 실시예의 조성물이 간 손상으로부터 간을 보호하는 효과가 있음을 확인할 수 있다. As shown in Table 5, the oral administration of the compositions of Examples 2, 3 and 6 showed the greatest decrease in ALT and AST activity, and the administration of the composition of Example reduced more than the administration of the composition of Comparative Example. It was. Therefore, it can be seen that the composition of the embodiment has an effect of protecting the liver from liver damage.
<< 실험예Experimental Example 2> 간 보호 효과 확인 2> Check the liver protection effect
약물이 유입되면 간에서 대사 작용이 일어남과 동시에 산화작용이 증가하여 지질과산화물이 생성되는데 이러한 지질과산화물은 간 손상을 증가시킬 수 있는 요인이 된다. 상기 실험예 1에서 사염화탄소로 간손상을 유발한 쥐의 지질과산화물을 측정하기 위하여 간 조직을 채취하였다. 채취한 간 조직을 생리식염수에 넣고 분쇄시킨 다음 ThioBarbituric Acid Reactive Substances(TBARS assay kit) 실험 방법에 따라 지질과산화물인 말론디알데하이드(MDA: malondialdehyde)를 측정하였다. 그 결과는 하기 표 6과 같다.When the drug is introduced, metabolism occurs in the liver and oxidative action increases to produce lipid peroxides. These lipid peroxides can increase liver damage. In Experimental Example 1, liver tissue was collected to measure lipid peroxides of rats that caused liver damage with carbon tetrachloride. The collected liver tissues were pulverized in physiological saline, and the lipid peroxide malondialdehyde (MDA) was measured according to the ThioBarbituric Acid Reactive Substances (TBARS assay kit) test method. The results are shown in Table 6 below.
상기 표 6에 나타난 바와 같이, 실시예의 조성물은 비교예의 조성물보다 사염화탄소 유발 지질과산화물 생성억제에 효과적이었다.As shown in Table 6, the composition of the Example was more effective in inhibiting the carbon tetrachloride-induced lipid peroxide production than the composition of the comparative example.
<< 실험예Experimental Example 3> 심장 기능 개선 효과 확인 3> Check the effect of improving heart function
심장 기능의 개선을 심장 비대에 대한 효과로 평가하였다. 7주령 수컷 랫트(190-200 g)에 대하여 수술로 복부 대동맥 협착을 수행하였다. 이러한 복부 대동맥 협착에 의해 수축기 혈압이 상승하고 심장의 후부하가 증대하여 과심실의 비대가 유발되었다. 상기 대동맥 협착 수술 1일 전부터 수술 후 15일간 지속적으로 1일 2회에 걸쳐 총 500 mg의 상기 실시예 및 비교예에서 제조한 조성물을 경구 투여하였다. 실험 종료 후 랫트를 마취시키고, 렛트의 체중과 혈행 동태를 마취 하에서 측정한 후 심장을 적출하여 심중량을 측정하였다. 체중에 대한 심장 중량의 비율을 심장 비대의 지표로 하였다. 그 결과는 하기 표 7과 같다. Improvement in heart function was assessed as an effect on cardiac hypertrophy. Abdominal aortic stenosis was performed surgically on 7 week old male rats (190-200 g). The abdominal aortic stenosis increases systolic blood pressure and increases the cardiac backload, causing hyperventricular hypertrophy. A total of 500 mg of the compositions prepared in Examples and Comparative Examples were administered orally twice a day continuously for 15 days after the surgery from one day before the aortic stenosis. After the end of the experiment, rats were anesthetized, the body weight and hemodynamics of the rats were measured under anesthesia, and the heart was extracted to determine heart weight. The ratio of heart weight to body weight was used as an indicator of cardiac hypertrophy. The results are shown in Table 7 below.
상기 표 7에 나타난 바와 같이, 실시예의 조성물을 투여한 경우 및 비교예의 조성물을 투여한 경우에 체중에 있어서 유의적인 차이는 나타나지 않았다. 또한, 비교예의 조성물을 투여한 경우 실시예의 조성물의 투여한 경우보다 유의적으로 심장 중량의 증가가 큰 반면, 실시예의 조성물을 투여한 경우 심장 중량의 증가가 상대적으로 적었고 심장 비대의 발생이 억제됨을 확인할 수 있었다.As shown in Table 7, there was no significant difference in body weight when the composition of the Example was administered and when the composition of the Comparative Example was administered. In addition, the administration of the composition of the comparative example was significantly higher in the weight of the heart than the administration of the composition of the example, while the administration of the composition of the example was relatively small increase in heart weight and suppressed the occurrence of cardiac hypertrophy. I could confirm it.
이상 첨부된 도면을 참조하여 본 발명의 실시예를 설명하였지만, 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자는 본 발명이 그 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다.While the present invention has been described in connection with what is presently considered to be practical exemplary embodiments, it is to be understood that the invention is not limited to the disclosed embodiments, but, on the contrary, You will understand. It is therefore to be understood that the above-described embodiments are illustrative in all aspects and not restrictive.
Claims (9)
타우린; 및
비타민 E, 코엔자임 Q10 또는 이들의 혼합물에서 선택된 비타민류를 포함하는 심장 및 간 기능 개선용 조성물. L-carnitine;
Taurine; And
A composition for improving heart and liver function comprising vitamins selected from vitamin E, coenzyme Q10 or mixtures thereof.
상기 L-카르니틴은 조성물에 대해 10 내지 35 중량부로 포함되는 심장 및 간 기능 개선용 조성물.The method of claim 1,
The L-carnitine is 10 to 35 parts by weight based on the composition composition for improving heart and liver function.
상기 타우린은 조성물에 대해 1 내지 30 중량부로 포함되는 심장 및 간 기능 개선용 조성물. The method of claim 1,
The taurine is a composition for improving heart and liver function is contained in 1 to 30 parts by weight based on the composition.
상기 코엔자임 Q10은 조성물에 대해 0.1 내지 5 중량부로 포함되는 심장 및 간 기능 개선용 조성물.The method of claim 1,
The coenzyme Q10 is 0.1 to 5 parts by weight based on the composition composition for improving heart and liver function.
상기 비타민 E가 조성물에 대해 0.1 내지 5 중량부로 포함되는 심장 및 간 기능 개선용 조성물.5. The method of claim 4,
The vitamin E is a composition for improving the heart and liver function is included 0.1 to 5 parts by weight with respect to the composition.
상기 조성물이 인간 또는 동물에게 적용될 수 있는 심장 및 간 기능 개선용 조성물.The method of claim 1,
Composition for improving heart and liver function that the composition can be applied to humans or animals.
아연을 더 포함하는 심장 및 간 기능 개선용 조성물.The method of claim 1,
Composition for improving heart and liver function further comprising zinc.
타우린; 및
비타민 E, 코엔자임 Q10 또는 이들의 혼합물에서 선택된 비타민류를 포함하는 심장 및 간 기능 개선용 기능성 식품.L-carnitine;
Taurine; And
A functional food for improving heart and liver function comprising vitamins selected from vitamin E, coenzyme Q10 or mixtures thereof.
상기 식품이 기능성 음료인 심장 및 간 기능 개선용 식품.9. The method of claim 8,
Food for improving heart and liver function wherein the food is a functional drink.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120023452A KR101671959B1 (en) | 2012-03-07 | 2012-03-07 | Composition for improving heart and liver function and Functional food comprising thererof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120023452A KR101671959B1 (en) | 2012-03-07 | 2012-03-07 | Composition for improving heart and liver function and Functional food comprising thererof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20130102307A true KR20130102307A (en) | 2013-09-17 |
KR101671959B1 KR101671959B1 (en) | 2016-11-03 |
Family
ID=49452101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120023452A KR101671959B1 (en) | 2012-03-07 | 2012-03-07 | Composition for improving heart and liver function and Functional food comprising thererof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101671959B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220083535A (en) * | 2020-12-11 | 2022-06-20 | (주)에이앤바이오 | Composition for improving companion animal heart function and functional food containing the same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060069850A (en) * | 2003-09-05 | 2006-06-22 | 마티아스 라트 | Pharmaceutical composition comprising i.a. vitamin c, magnesium, green tea extract for retarding cardiovascular diseases |
KR20110119305A (en) * | 2010-04-27 | 2011-11-02 | 김원규 | A functional beverage comprising taurine, royal jelly, red ginseng, lycii fructus, glumate and apple essence as main ingredients |
KR20120010680A (en) * | 2010-07-27 | 2012-02-06 | 김원규 | A functional beverage composition comprising taurine, L-carnitine, vitamin C, vitamine B complex, and color selected from caramel color and sepia color |
-
2012
- 2012-03-07 KR KR1020120023452A patent/KR101671959B1/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060069850A (en) * | 2003-09-05 | 2006-06-22 | 마티아스 라트 | Pharmaceutical composition comprising i.a. vitamin c, magnesium, green tea extract for retarding cardiovascular diseases |
KR20110119305A (en) * | 2010-04-27 | 2011-11-02 | 김원규 | A functional beverage comprising taurine, royal jelly, red ginseng, lycii fructus, glumate and apple essence as main ingredients |
KR20120010680A (en) * | 2010-07-27 | 2012-02-06 | 김원규 | A functional beverage composition comprising taurine, L-carnitine, vitamin C, vitamine B complex, and color selected from caramel color and sepia color |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220083535A (en) * | 2020-12-11 | 2022-06-20 | (주)에이앤바이오 | Composition for improving companion animal heart function and functional food containing the same |
Also Published As
Publication number | Publication date |
---|---|
KR101671959B1 (en) | 2016-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2006338273B2 (en) | All natural multivitamin and multimineral dietary supplement formulations for enhanced absorption and biological utilization | |
US8029830B2 (en) | Composition and method for promoting internal health and external appearance | |
US7063861B2 (en) | Bioavailable composition of natural and synthetic HCA | |
EP3345608A1 (en) | Method for inhibiting absorption of and/or promoting excretion of lipids using d-psicose | |
KR20070109981A (en) | Composition for body fat reduction | |
KR20210153027A (en) | Anti-aging agents and anti-aging methods | |
US20100173856A1 (en) | Methods of producing and using nutritional and pharmaceutical compositions that include one or more active substances | |
KR20090064398A (en) | Olive extracts for promoting muscle health | |
US20090169490A1 (en) | Composition and method for weight loss | |
TWI225789B (en) | Compositions inhibiting muscle atrophy | |
KR20220154210A (en) | Coenzyme Q production promoter and coenzyme Q production promotion method | |
US20200375237A1 (en) | Co-Q10, Krill Oil and Vitamin D | |
US10925845B2 (en) | Stability of vitamin D in β-hydroxy-β-methylbutyrate (HMB) | |
KR101671959B1 (en) | Composition for improving heart and liver function and Functional food comprising thererof | |
KR20190131817A (en) | A ginsenoside complex comprising insoluble substance curcumin | |
KR20130102305A (en) | Composition for liver protection and improving liver function and functional food comprising thererof | |
KR101574536B1 (en) | Composition for promoting growth comprising coumaric acid | |
WO2017146560A1 (en) | Anti-aging supplement | |
KR20090099945A (en) | A composition comprising the extract of raphani semen as an active ingredient showing anti-obesity and anti-hyperlipidemia activity | |
US9937220B2 (en) | Anti-diabetic nutraceutical composition from palm leaf extract | |
US20220040205A1 (en) | Stability of vitamin d in beta-hydroxy- beta-methylbutyrate (hmb) | |
KR20140026737A (en) | A composition comprising the powder of fermented curcuma longa l. for protecting alcoholic liver damage | |
US20240148026A1 (en) | Liquid-phase, supplementary feed composition containing coenzyme q10 | |
KR20240094564A (en) | Pharmaceutical composition for improving, preventing or treating fatty liver disease comprising methyl linoleate | |
AU2012200083B2 (en) | All natural multivitamin and multimineral dietary supplement formulations for enhanced absorption and biological utilization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right |